Source: Health Canada shortage reports · Updated Sep 23, 2026
Labetalol is in a widespread shortage in Canada. 5 of 9 reported products are affected. The latest manufacturer estimate for full recovery is Oct 16, 2026.
A beta blocker used to treat high blood pressure, including during pregnancy.
Products affected
5 / 9
In shortage since
Nov 8, 2024
Est. full return
Oct 16, 2026
Reports on file
40
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
LABETALOL HYDROCHLORIDE INJECTION USP
5MG · SOLUTION · JAMP PHARMA CORPORATION
DIN 02541505 · since Sep 15, 2026, est. end Oct 16, 2026 · Disruption of the manufacture of the drug.
Active shortage
LABETALOL HYDROCHLORIDE INJECTION
5MG · SOLUTION · OMEGA LABORATORIES LIMITED
DIN 02457040 · since May 13, 2026, no end estimate · Disruption of the manufacture of the drug.
Active shortage
APO-LABETALOL
200MG · TABLET · APOTEX INC
DIN 02243539 · since Mar 31, 2026, est. end May 8, 2026 · Disruption of the manufacture of the drug.
Active shortage
TRANDATE
200MG · TABLET · PALADIN PHARMA INC.
DIN 02106280 · since Nov 8, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
TRANDATE
100MG · TABLET · PALADIN PHARMA INC.
DIN 02106272 · since Nov 8, 2024, no end estimate · Disruption of the manufacture of the drug.
DIN 02231689 · ended Feb 10, 2025 · Demand increase for the drug.
Discontinued
LABETALOL HYDROCHLORIDE INJECTION, USP
5MG · SOLUTION · MYLAN PHARMACEUTICALS ULC
DIN 02387468
Resolved
LABETALOL HYDROCHLORIDE INJECTION, USP
5MG · SOLUTION · MYLAN PHARMACEUTICALS ULC
DIN 02387468 · ended Jan 10, 2023 · Demand increase for the drug.
Resolved
APO-LABETALOL
200MG · TABLET · APOTEX INC
DIN 02243539 · ended Nov 28, 2024 · Disruption of the manufacture of the drug.
Showing 12 of 40 reports. All reports are on file with Health Canada.
What's happening
Labetalol is currently affected by 5 active shortage reports filed with Health Canada by JAMP PHARMA CORPORATION, OMEGA LABORATORIES LIMITED, APOTEX INC, PALADIN PHARMA INC..
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Labetalol is classified under “BETA BLOCKING AGENTS” (ATC C07AG).
Recent changes
Sep 23, 2026
New report filed
Aug 5, 2026
New report filed
Common questions
What is Labetalol used for?
A beta blocker used to treat high blood pressure, including during pregnancy.
When will Labetalol be back in stock in Canada?
The latest manufacturer estimate is Oct 16, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Labetalol in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.